Clinical features of the study cohort
| Characteristics . | Control (n = 132) . | PcGVHD(n = 166) . | Unclassified (n = 52) . | P . | |
|---|---|---|---|---|---|
| Age at HCT* | 39.8 ± 16.8 | 40.7 ± 15.5 | 35.3 ± 18.7 | .114 | |
| Weight, kg* | 72.0 ± 20.5 | 68.5 ± 16.7 | 67.1 ± 20.4 | .170 | |
| KPS* | 83.0 ± 9.7 | 74.6 ± 12.0 | 77.6 ± 12.0 | <.001 | |
| TLC, %predicted* | 95.3 ± 13.4 | 74.2 ± 17.9 | 76.4 ± 15.4 | <.001 | |
| RV, %predicted* | 88.1 ± 32.5 | 90.6 ± 42.0 | 89.8 ± 37.7 | .845 | |
| FEV1/FVC, %, pre-bronchodilator* | 79.4 ± 7.9 | 64.9 ± 18.1 | 76.3 ± 13.1 | <.001 | |
| FVC, %predicted, pre-bronchodilator* | 96.6 ± 12.4 | 62.7 ± 17.2 | 67.5 ± 15.0 | <.001 | |
| FEV1, %predicted, pre-bronchodilator* | 97.4 ± 12.8 | 50.3 ± 16.3 | 64.0 ± 14.2 | <.001 | |
| FEF 25-75%, %predicted* | 94.0 ± 27.9 | 39.9 ± 31.9 | 57.8 ± 26.5 | <.001 | |
| DLCO adj, %predicted* | 74.8 ± 18.4 | 53.7 ± 16.7 | 57.9 ± 16.7 | <.001 | |
| Different types of cGVHD treatment*,† | 3.8 ± 1.9 | 5.1 ± 2.2 | 5.2 ± 2.2 | <.001 | |
| Time from HCT to cGVHD diagnosis (days)* | 395.1 ± 741.0 | 319.7 ± 345.8 | 282.0 ± 208.7 | .308 | |
| Time from HCT to adjudicative PFT (days)* | 1822.8 ± 1640.6 | 2113.6 ± 1579.2 | 1869.6 ± 1345.4 | .253 | |
| Recipient sex‡ | Female | 62 (46.9) | 74 (44.6) | 20 (38.4) | .579 |
| Recipient race‡ | White | 112 (86.2) | 148 (89.2) | 47 (90.4) | .635 |
| HCT location‡ | Local | 113 (85.6) | 154 (92.8) | 45 (86.5) | .115 |
| NIH | 19 (14.4) | 12 (7.2) | 7 (13.5) | ||
| Pre-HCT tobacco use‡ | 34 (25.9) | 51 (30.7) | 12 (23.1) | .471 | |
| HCT indication‡ | AML, MDS, ALL | 61 (46.2) | 96 (57.8) | 26 (50.0) | .037 |
| CML, MPN | 16 (12.1) | 19 (11.5) | 3 (5.8) | ||
| CLL, HL, NHL, MM | 48 (36.4) | 43 (25.9) | 15 (28.9) | ||
| Others | 7 (5.3) | 8 (4.8) | 8 (15.4) | ||
| Disease status at HCT‡ | CR | 47 (39.8) | 92 (60.1) | 21 (44.7) | .003 |
| HLA‡ | MRD | 69 (52.7) | 90 (54.2) | 18 (36.7) | .037 |
| MUD | 40 (30.5) | 53 (31.9) | 28 (57.1) | ||
| MMUD | 16 (12.2) | 16 (9.6) | 2 (4.1) | ||
| Haploidentical | 6 (4.6) | 7 (4.2) | 1 (2.0) | ||
| Stem cell source‡ | PB | 98 (77.2) | 138 (84.2) | 38 (73.1) | .233 |
| BM | 29 (22.8) | 26 (15.9) | 12 (23.1) | ||
| Conditioning‡ | RIC | 71 (53.8) | 69 (42.1) | 25 (50.0) | .126 |
| MAC | 61 (46.2) | 95 (57.9) | 25 (50.0) | ||
| Busulfan‡ | 44 (34.4) | 76 (48.1) | 16 (32.0) | .026 | |
| TBI‡ | 54 (41.2) | 64 (39.0) | 20 (39.2) | .924 | |
| GVHD prophylaxis | CNI + MTX | 62 (50.8) | 70 (46.1) | 29 (59.2) | .269 |
| Second malignancy‡ | 20 (15.1) | 34 (20.5) | 10 (19.2) | .488 | |
| Acute GVHD‡ | 92 (69.7) | 120 (72.3) | 38 (73.1) | .851 | |
| cGVHD global | Mild | 6 (4.5) | 1 (0.6) | 0 | <.001 |
| severity‡ | Moderate | 50 (37.9) | 15 (9.0) | 13 (25.0) | |
| Severe | 76 (57.6) | 150 (90.4) | 39 (75.0) | ||
| Relapse/refractory primary malignancy‡ | 22 (16.7) | 22 (13.3) | 8 (15.4) | .708 | |
| Characteristics . | Control (n = 132) . | PcGVHD(n = 166) . | Unclassified (n = 52) . | P . | |
|---|---|---|---|---|---|
| Age at HCT* | 39.8 ± 16.8 | 40.7 ± 15.5 | 35.3 ± 18.7 | .114 | |
| Weight, kg* | 72.0 ± 20.5 | 68.5 ± 16.7 | 67.1 ± 20.4 | .170 | |
| KPS* | 83.0 ± 9.7 | 74.6 ± 12.0 | 77.6 ± 12.0 | <.001 | |
| TLC, %predicted* | 95.3 ± 13.4 | 74.2 ± 17.9 | 76.4 ± 15.4 | <.001 | |
| RV, %predicted* | 88.1 ± 32.5 | 90.6 ± 42.0 | 89.8 ± 37.7 | .845 | |
| FEV1/FVC, %, pre-bronchodilator* | 79.4 ± 7.9 | 64.9 ± 18.1 | 76.3 ± 13.1 | <.001 | |
| FVC, %predicted, pre-bronchodilator* | 96.6 ± 12.4 | 62.7 ± 17.2 | 67.5 ± 15.0 | <.001 | |
| FEV1, %predicted, pre-bronchodilator* | 97.4 ± 12.8 | 50.3 ± 16.3 | 64.0 ± 14.2 | <.001 | |
| FEF 25-75%, %predicted* | 94.0 ± 27.9 | 39.9 ± 31.9 | 57.8 ± 26.5 | <.001 | |
| DLCO adj, %predicted* | 74.8 ± 18.4 | 53.7 ± 16.7 | 57.9 ± 16.7 | <.001 | |
| Different types of cGVHD treatment*,† | 3.8 ± 1.9 | 5.1 ± 2.2 | 5.2 ± 2.2 | <.001 | |
| Time from HCT to cGVHD diagnosis (days)* | 395.1 ± 741.0 | 319.7 ± 345.8 | 282.0 ± 208.7 | .308 | |
| Time from HCT to adjudicative PFT (days)* | 1822.8 ± 1640.6 | 2113.6 ± 1579.2 | 1869.6 ± 1345.4 | .253 | |
| Recipient sex‡ | Female | 62 (46.9) | 74 (44.6) | 20 (38.4) | .579 |
| Recipient race‡ | White | 112 (86.2) | 148 (89.2) | 47 (90.4) | .635 |
| HCT location‡ | Local | 113 (85.6) | 154 (92.8) | 45 (86.5) | .115 |
| NIH | 19 (14.4) | 12 (7.2) | 7 (13.5) | ||
| Pre-HCT tobacco use‡ | 34 (25.9) | 51 (30.7) | 12 (23.1) | .471 | |
| HCT indication‡ | AML, MDS, ALL | 61 (46.2) | 96 (57.8) | 26 (50.0) | .037 |
| CML, MPN | 16 (12.1) | 19 (11.5) | 3 (5.8) | ||
| CLL, HL, NHL, MM | 48 (36.4) | 43 (25.9) | 15 (28.9) | ||
| Others | 7 (5.3) | 8 (4.8) | 8 (15.4) | ||
| Disease status at HCT‡ | CR | 47 (39.8) | 92 (60.1) | 21 (44.7) | .003 |
| HLA‡ | MRD | 69 (52.7) | 90 (54.2) | 18 (36.7) | .037 |
| MUD | 40 (30.5) | 53 (31.9) | 28 (57.1) | ||
| MMUD | 16 (12.2) | 16 (9.6) | 2 (4.1) | ||
| Haploidentical | 6 (4.6) | 7 (4.2) | 1 (2.0) | ||
| Stem cell source‡ | PB | 98 (77.2) | 138 (84.2) | 38 (73.1) | .233 |
| BM | 29 (22.8) | 26 (15.9) | 12 (23.1) | ||
| Conditioning‡ | RIC | 71 (53.8) | 69 (42.1) | 25 (50.0) | .126 |
| MAC | 61 (46.2) | 95 (57.9) | 25 (50.0) | ||
| Busulfan‡ | 44 (34.4) | 76 (48.1) | 16 (32.0) | .026 | |
| TBI‡ | 54 (41.2) | 64 (39.0) | 20 (39.2) | .924 | |
| GVHD prophylaxis | CNI + MTX | 62 (50.8) | 70 (46.1) | 29 (59.2) | .269 |
| Second malignancy‡ | 20 (15.1) | 34 (20.5) | 10 (19.2) | .488 | |
| Acute GVHD‡ | 92 (69.7) | 120 (72.3) | 38 (73.1) | .851 | |
| cGVHD global | Mild | 6 (4.5) | 1 (0.6) | 0 | <.001 |
| severity‡ | Moderate | 50 (37.9) | 15 (9.0) | 13 (25.0) | |
| Severe | 76 (57.6) | 150 (90.4) | 39 (75.0) | ||
| Relapse/refractory primary malignancy‡ | 22 (16.7) | 22 (13.3) | 8 (15.4) | .708 | |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CR, complete remission; HL, Hodgkin’s lymphoma; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMUD, mismatched unrelated donor; MPN, myeloproliferative neoplasm; MRD, matched related donor; MUD, matched unrelated donor; NHL, non-Hodgkin’s lymphoma; PB, peripheral blood; RIC, reduced intensity conditioning; RV, residual volume; TBI, total body irradiation.
Mean ± SD, analysis of variance test.
Excluding topical treatment such as topical corticosteroids.
Count (percentage), χ2 test.